Fluvoxamine for COVID-19: real-time meta analysis of 17 studies

• Statistically significant improvements are seen for mortality, hospitalization, and cases. 11 studies from 11 independent teams in 6 different countries show statistically significant improvements in isolation (5 for the most serious outcome).• Meta analysis using the most serious outcome reported shows 38% [19‑52%] improvement. Results are slightly worse for Randomized Controlled Trials and similar for peer-reviewed studies. • Results are robust — in exclusion sensitivity analysis 9 of 17 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.• Treatment recommendations are available from Ontario. • No treatment, vaccine, or intervention is 100% effective and available. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. Only 12% of fluvoxamine studies show zero events with treatment. • All data to reproduce this paper and sources are in the appendix. Other meta analyses for fluvoxamine can be found in [Deng, Lee, Lu, Marcec, Nakhaee], showing significant improvements for mortality, hospitalization, and severity.

Percentage improvement with fluvoxamine (more)

	Late treatment	Early treatment	All studies	Studies	Patients	Authors
All studies	51% [25‑68%]**	43% [-10‑70%]	38% [19‑52%]***	17	36,705	414
Randomized Controlled TrialsRCTs	32% [-22‑62%]	28% [-17‑56%]	30% [-1‑51%]	8	5,739	337
Mortality	51% [22‑69%]**	65% [-1506‑99%]	41% [8‑62%]*	8	4,224	130
HospitalizationHosp.	22% [-3‑41%]	37% [-4‑61%]	25% [6‑40%]*	10	6,384	356
Cases	-	-	25% [11‑36%]***	2	9,116	10
RCT mortality	30% [-26‑63%]	-200% [-7253‑88%]	27% [-33‑60%]	2	2,973	62